

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Zurampic (lesinurad)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Zurampic (lesinurad)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Zurampic (lesinurad) may be approved if the following criteria are met:

- I. Individual has had a previous trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response (unable to achieve target serum uric acid levels) to one preferred xanthine oxidase inhibitor (allopurinol, febuxostat*); **AND**
- II. Individual has hyperuricemia associated with gout; **AND**
- III. Individual is unable to achieve target serum uric acid levels while on a xanthine oxidase inhibitor (such as allopurinol or febuxostat*); **AND**
- IV. Individual remains symptomatic (such as, but not limited to joint pain, swelling, limited range of motion, erythema) despite use of xanthine oxidase inhibitor; **AND**
- V. Individual will continue use of a xanthine oxidase inhibitor in conjunction with Zurampic.

*requires prior authorization

Zurampic (lesinurad) may not be approved for the following:

- I. Individual has severe renal impairment (creatinine clearance less than 30 mL/min), end stage renal disease, is on dialysis or is a kidney transplant recipient; **OR**
- II. Individual has Lesch-Nyhan syndrome or tumor lysis syndrome.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Note: Zurampic (lesinurad) has a black box warning indicating risk of acute renal failure is more common when Zurampic is used without a xanthine oxidase inhibitor. Zurampic should be used in combination with a xanthine oxidase inhibitor.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: March 28, 2019.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.
CRX-ALL-0429-19